⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bukwang Pharmaceutical Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Bukwang Pharmaceutical Co., Ltd.
↗Seoul, South Korea
Bukwang Pharmaceutical is a South Korean pharmaceutical company established in 1960. It focuses on the development, manufacturing, and marketing of ethical drugs, over-the-counter medications, and health supplements, with a strong strategic emphasis on Central Nervous System (CNS) disorders, oncology, and metabolic diseases.
Following its 2022 acquisition by OCI Holdings, the company has undergone a structural transformation, including the establishment of a dedicated CNS Business Division and a shift toward a contract sales organization (CSO) model to improve profitability. The company actively pursues open innovation through strategic investments, joint ventures, and international partnerships to expand its drug pipeline.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:CNS therapeutics, Oncology, Metabolic diseases
SIZE & FINANCIALS
Employees:501-1000
Revenue:$150M-$200M
Founded:1960
Ownership:public
Status:operating
FUNDING
Investors:OCI Holdings
STOCK
Exchange:KRX
Ticker:003000
Market Cap:$0.20B
PIPELINE
Stage:Phase 2
Lead Drug Stage:Commercial (Latuda)
Modalities:Small molecule, Oligonucleotide
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:OCI Holdings
Acquired By:OCI Holdings (2022-02-01)
Subsidiaries:Contera Pharma A/S, Bukwang Medica, Dyna Therapeutics, Union Korea Pharm
Key Partnerships:OCI Holdings (Joint Management), University of Oxford (CNS research), University of Dundee (Parkinson's research), Lundbeck (Contera Pharma collaboration)
COMPETITION
Position:Challenger
Competitors:Chong Kun Dang, Dong-A ST, SK Biopharmaceuticals, Celltrion
LEADERSHIP
Key Executives:
Lee Jae-young - CEO and President
Mi-Chung Ahn - Chairman
LINKS
Website:bukwang.co.kr
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bukwang Pharmaceutical Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.